ABSTRACT
A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases. Patients in Study 1 received bleomycin, CCNU, or streptozotocin and those in Study 2 received tilorone, Baker's antifol, or a combination of 5-fluorodeoxyuridine plus arabinosyl cytosine. Partial responses were seen only with bleomycin, Baker's antifol, and 5-fluorodeoxyuridine plus arabinosyl cytosine. The median times to treatment failure ranged from 3.6 weeks to 5.7 weeks, and the median survival times, from 8 weeks to 25 weeks for tilorone and bleomycin, respectively. Toxic reactions was primarily hematologic and gastrointestinal, but skin, neurologic, respiratory, and renal abnormalities were noted in some treatment arms. The treatment schedules outlined and the toxic effects noted provide background information that might prove useful in designing complex new chemotherapeutic programs, since there is pharmacological rationale for incorporating some of the agents tested into present standard combination chemotherapy regimens.
Subject(s)
Antineoplastic Agents/administration & dosage , Breast Neoplasms/drug therapy , Antineoplastic Agents/adverse effects , Bleomycin/administration & dosage , Breast Neoplasms/mortality , Cytarabine/administration & dosage , Drug Evaluation , Drug Therapy, Combination , Female , Floxuridine/administration & dosage , Humans , Lomustine/administration & dosage , Probability , Streptozocin/administration & dosage , Tilorone/administration & dosage , Triazines/administration & dosageABSTRACT
Fifty-nine patients with metastatic melanoma predominantly localized in the skin were randomly assigned to treatment with BCG given either intralesionally (IL-BCG) or by multiple puncture vaccination at a nontumor bearing site in the skin (MPV-BCG). Half the patients with IL-BCG experienced moderate fever, chills and malaise, suggesting systemic exposure to this live organism. However, only three of these patients required systemic antituberculous chemotherapy and all responded to it. MPV-BCG treated patients experienced significantly less systemic toxicity. Among fully evaluable patients 45% objective response rate was seen in the IL-BCG group and a 9% response rate in the MPV-BCG group, a significant difference. The only complete responses were seen in the IL-BCG group. Among fully evaluable patients, median survival was 21.1 months in the IL-BCG group and 13.3 months in the MPV-BCG groups (NSD). No patients with pretreatment anergy to all skin tests utilized, experienced objective response to BCG.
Subject(s)
BCG Vaccine/administration & dosage , Melanoma/therapy , Skin Neoplasms/therapy , Adult , Aged , BCG Vaccine/adverse effects , Clinical Trials as Topic , Evaluation Studies as Topic , Fever/etiology , Humans , Melanoma/immunology , Middle Aged , Neoplasm Metastasis , Punctures , Skin Neoplasms/immunology , Skin Tests , Thrombocytopenia/etiologyABSTRACT
A controlled trial of high-intermittent vs low-chronic dose cyclophosphamide in human lung cancer failed to show the benefits reported in noncontrolled trials. There were no differences in toxicity observed.
Subject(s)
Cyclophosphamide/administration & dosage , Lung Neoplasms/drug therapy , Adult , Aged , Clinical Trials as Topic , Cyclophosphamide/adverse effects , Drug Administration Schedule , Female , Hematopoiesis/drug effects , Humans , Male , Middle Aged , Time Factors , Vomiting/chemically inducedABSTRACT
Phenesterin was evaluated in 222 patients with two different dosage regimens, one by daily treatment and the other with an intermittent schedule. Toxicity was moderate with both programs. The largest group of patients treated had breast cancer; they experienced a 10% response rate. Of interest was a higher percentage of responses in ovarian cancer (36%). An expanded study of patients with ovarian cancer would be of interest.
Subject(s)
Nitrogen Mustard Compounds/therapeutic use , Adult , Aged , Breast Neoplasms/drug therapy , Clinical Trials as Topic , Evaluation Studies as Topic , Female , Humans , Male , Middle Aged , Nitrogen Mustard Compounds/administration & dosage , Nitrogen Mustard Compounds/adverse effects , Ovarian Neoplasms/drug therapyABSTRACT
This report is the result of an Eastern Cooperative Oncology Group (ECOG) study. Four hundred and 15 patients with inoperable metastatic malignant melanoma, excluding those with cutaneous metastases only, were randomized to one of three drug treatments: DTIC alone, methyl-CCNU alone, or the combination DTIC plus methyl-CCNU. Responses were seen in 14% of DTIC patients (19/127), 15% of methyl-CCNU patients (18/119) and 14% of DTIC plus methyl-CCNU patients (18/122). Duration of response was the same (14 weeks) for all three treatment groups. There was no difference among the treatments in achieving complete responses. Survival was improved significantly for responders (50 weeks) compared with nonresponders (15 weeks) regardless of treatment regimen. Toxicities were generally tolerable. DTIC caused significantly more gastrointestinal toxicity than methyl-CCNU. Methyl-CCNU caused significantly more bone marrow toxicity than DTIC. There were three drug-related deaths. All occurred in patients on combination DTIC plus methyl-CCNU. Important pretreatment characteristics that favor response are ambulatory status, female, less than 50 years old, no prior chemotherapy and no liver or brain metastases. Patients with favorable characteristics combinations had a 30% response rate, while those with unfavorable characteristic combinations had only a 9% response rate.
Subject(s)
Dacarbazine/therapeutic use , Melanoma/drug therapy , Nitrosourea Compounds/therapeutic use , Semustine/therapeutic use , Triazenes/therapeutic use , Brain Neoplasms/drug therapy , Chemical and Drug Induced Liver Injury , Clinical Trials as Topic , Dacarbazine/adverse effects , Drug Therapy, Combination , Female , Humans , Liver Neoplasms/drug therapy , Male , Neoplasm Metastasis/drug therapy , Prognosis , Remission, Spontaneous , Semustine/adverse effects , Thrombocytopenia/chemically induced , Time FactorsABSTRACT
Two hundred and fifty-eight patients with small cell carcinoma and 185 patients with adenocarcinoma were centrally randomized to receive either cyclophosphamide (1000 mg/m2 every 3 weeks) iv or cyclophosphamide (700 mg/m2 every 3 weeks) iv plus CCNU (70 mg/m2 every 6 weeks) orally. Those patients who were initially treated with the single agent were then treated with CCNU (130 mg/m2 every 6 weeks) at the time of cyclophosphamide failure. Objective tumor regression occurred more frequently with the combination regimen in patients with small cell carcinoma (43% vs 22%, P = 0.002), but no difference in response rates was apparent in patients with adenocarcinoma. In both cell types patients survived somewhat longer following treatment with the combination. The overall incidence of severe toxicity was equal for the two regimens in both cell types; however, the therapeutic index of the combination was superior to that of the single agent in small cell carcinoma. Severe drug toxicity was more frequent in small cell carcinoma patients with extensive disease, and survival was reduced in both cell types with extensive disease. Survival was better for ambulatory patients in both cell types and women survived longer than men. In women with small cell carcinoma, ambulatory status also was associated with a higher incidence of tumor regression. In patients with small cell carcinoma those who had prior lung surgery survived longer than those without prior surgery. Previous radiation therapy was associated with a reduced incidence of objective regression in men with small cell carcinoma. In both cell types patients with tumor regression lived longer than nonresponders; however, objective disease stability was associated with improved survival only in patients with adenocarcinoma. Stratification in future studies should consider extent of disease, performance status, sex, and prior therapy.
Subject(s)
Adenocarcinoma/drug therapy , Carcinoma/drug therapy , Cyclophosphamide/therapeutic use , Lomustine/therapeutic use , Lung Neoplasms/drug therapy , Nitrosourea Compounds/therapeutic use , Adult , Aged , Cyclophosphamide/adverse effects , Drug Therapy, Combination , Female , Humans , Lomustine/adverse effects , Male , Middle Aged , PrognosisSubject(s)
Carcinoma/drug therapy , Doxorubicin/therapeutic use , Lung Neoplasms/drug therapy , Adult , Aged , Drug Evaluation , Female , Humans , Male , Middle Aged , PrognosisABSTRACT
5-Azacytidine was administered daily to 12 patients in a five-day schedule and to 15 patients in a weekly schedule as part of a phase I trial. The daily dose ranged from 50 mg/m2 to 158 mg/m2 and the weekly dose, from 200 mg/m2 to 633 mg/m2. The maximum total dose was 2000 mg in the daily schedule and 3775 mg in the weekly schedule. The major toxicity was gastrointestinal, with nausea and vomiting occurring in all patients in this study. Myelosuppression was less frequently encountered and appeared to be related to the increase in 5-azacytidine dose. Patients receiving 5-azacytidine in a weekly schedule of administration appeared to tolerate the drug better and to be more willing to continue their therapy.
Subject(s)
Azacitidine/therapeutic use , Neoplasms/drug therapy , Azacitidine/administration & dosage , Azacitidine/adverse effects , Clinical Trials as Topic , Drug Administration Schedule , HumansABSTRACT
This prospective randomized Eastern Cooperative Oncology Group (ECOG) study (1071) was designed to compare a new and promising cytotoxic agent TIC Mustard (triazeno imidazole carboxamide mustard, NSC 82196) with DTIC (dimethyl triazeno imidazole carboxamide, NSC 45388) in the treatment of inoperable melanoma. One hundred and seventy-eight patients were randomized to receive either DTIC (150 mg/m2/day X 5) or TIC Mustard (800 mg/m2/day X 5). Of this group 145 patients were evaluable for tumor response at the completion of the study. Objective responses were seen in 15/79 (19.0%) DTIC patients and 4/66 (6.1%) TIC Mustard patients. Adjustment of crude response rates yielded final response rates of 18.2% for DTIC patients and 5.8% for TIC Mustard. These differences were significant at the p less than or equal to .03 level. Median response duration was 15 weeks for the DTIC responders and 4 weeks for the TIC Mustard responders. Responders and nonresponders did not differ significantly in any of the standard prognostic categories. However, responders had a significantly longer median survival (47.5 weeks) compared to that for nonresponders (17.8 weeks). Toxicity was tolerable for either drug and no deaths were ascribed to either. We conclude that TIC Mustard has limited usefulness in the treatment of malignant melanoma and is less effective than DTIC.
Subject(s)
Dacarbazine/therapeutic use , Imidazoles/therapeutic use , Melanoma/drug therapy , Nitrogen Mustard Compounds/therapeutic use , Triazenes/therapeutic use , Clinical Trials as Topic , Dacarbazine/administration & dosage , Dacarbazine/adverse effects , Drug Evaluation , Female , Humans , Imidazoles/administration & dosage , Imidazoles/adverse effects , Male , Nitrogen Mustard Compounds/administration & dosage , Nitrogen Mustard Compounds/adverse effects , Prospective StudiesABSTRACT
One hundred and ninety-seven patients with measurable metastatic cancer of the colon have been treated with one of four anticancer drugs which have had little prior trial in this disease. Objective tumor responses lasting a median of 9 weeks occurred with 0.5 g/m of streptozotocin given intravenously every week (10 percent), 130 mg/m of CCNU given orally every 6 weeks (10%), 1.0 mg/kg/day of 6-thioguanine given orally (8%), and 3 mg/kg/day of procarbazine given orally (3%). Performance status declined more rapidly with streptozotocin and 6-thioguanine and the median survival time was less (12 and 16 weeks respectively) than with procarbazine and CCNU (23 and 20 weeks respectively). This study suggests that procarbazine given in this way is ineffective but trials of streptozotocin or 6-thioguanine combined with other agents active against colon cancer should ensue as well as further exploration of the usefulness of other nitrosoureas.
Subject(s)
Colonic Neoplasms/drug therapy , Lomustine/therapeutic use , Nitrosourea Compounds/therapeutic use , Procarbazine/therapeutic use , Streptozocin/therapeutic use , Thioguanine/therapeutic use , Clinical Trials as Topic , Drug Evaluation , Drug Therapy, Combination , Humans , Lomustine/adverse effects , Neoplasm Metastasis , Procarbazine/adverse effects , Streptozocin/adverse effects , Thioguanine/adverse effectsABSTRACT
Sixty patients with metastatic or primary inoperable breast cancer not suitable for hormone alteration therapy were blindly randomized between weekly 5-fluorouracil, intravenously, and daily physiologic doses of conjugated estrogens by mouth against weekly 5-fluorouracil, intravenously, and placebo. There was no difference in the survival or the effect on the tumor in the two groups. Numerous factors were analyzed as to their effect on the course of the disease. The number of organ sites of tumor involvement, age of the host, and previous treatment for the disseminated disease were not shown to influence the survival or the results of therapy of either group. However, the duration of the clinical cancer-free period from primary treatment to recurrence, the sites of organ involvement, and the performance status of the patients at the time of entry into the study significantly did influence the survival. There is no evidence in this study that physiologic doses of conjugated estrogens deleteriously influenced the course of the disease.
Subject(s)
Breast Neoplasms/drug therapy , Estrogens, Conjugated (USP)/therapeutic use , Fluorouracil/therapeutic use , Adult , Aged , Breast Neoplasms/pathology , Dose-Response Relationship, Drug , Drug Therapy, Combination , Estrogens, Conjugated (USP)/adverse effects , Female , Fluorouracil/adverse effects , Humans , Injections, Intravenous , Middle Aged , Neoplasm Metastasis , Prognosis , Remission, Spontaneous , Time FactorsABSTRACT
53 patients with intractable malignant diseases that were treated with a new alkylating agent, 4-N,N-bis (2-chloroethyl) amino phenyl N (P-carboxyphenyl) carbanate, also knows as 'IC-140' were evaluated. The records of an additional 41 patients entered on this study could not be assessed from the standpoint of toxicity. At the dose level of 150 mg/m2/week, severe leukopenia (less than 2,000) and thrombocytopenia ( less than 75,000) were encountered in 23 of 34 patients. On the other hand, at the 100 mg/m2/week dose level, the severe toxicity was reduced to 8 out of 19 patients. Tumor response was evaluated in 43 patients. The overall response was 23% (29% at the 150 mg/m2, 13% at the 100 mg/m2) and the duration of the response varied from 3 to 32 weeks with a mean duration of 13 weeks. Responses were noted in patients with ovarian, renal, lung, hepatic, breast carcinomas and lymphosarcoma.